Since the most widely used form of targeted therapy for breast cancer remains anti-oestrogen endocrine therapy, it is important to know if the ERα status of DTCs corresponds to the ERα status of the primary tumour, particularly in view of the 15 to 20% relapse rate in early stage ERα-positive tumours despite adjuvant endocrine therapy [9]. This evidence concerns the gene ESR1 and neoplasm.